Boston Scientific Corp. (BSX) is facing a turbulent period, with its stock price reaching an 18-month low due to concerns about the performance of its most awaited medical device.
The news follows mixed Q4 2025 earnings, and Q4 results in line with expectations despite a drop in shares. However, analysts cut their forecasts after the Q4 results and
the company's cautious 2026 revenue forecast caused further concern.
Boston Scientific has also seen its price targets cut but maintains a buy rating.
This tumultuous period is not without positive points, as
BSX has reported a Q4 profit and met their 2025 financial targets. Additionally, the company acquired Penumbra Inc, a move seen as bullish by some analysts. However, a fraud investigation has also been announced, urging affected shareholders to contact legal offices. Amid all these events,
BSX shares fluctuate greatly, yet some regarding this as a ripe period for a possible turnaround pointing to strong fundamentals and a bullish case theory.
Boston Scientific Corp BSX News Analytics from Mon, 15 Sep 2025 07:00:00 GMT to Sat, 07 Feb 2026 13:12:41 GMT -
Rating -2
- Innovation 4
- Information 5
- Rumor -1
